Cart
sales@molnova.com
JAK3/BTK-IN-1
CAS No. 2674036-91-8
JAK3/BTK-IN-1( —— )
Catalog No. M37669 CAS No. 2674036-91-8
JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important targets in autoimmune diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 586 | In Stock |
|
| 10MG | 834 | In Stock |
|
| 25MG | 1264 | In Stock |
|
| 50MG | 1600 | In Stock |
|
| 100MG | 2409 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJAK3/BTK-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionJAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important targets in autoimmune diseases.
-
DescriptionJAK3/BTK-IN-1 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBTK | JAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2674036-91-8
-
Formula Weight456.54
-
Molecular FormulaC25H28N8O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C1=C2C(=CNC2=NC(NC3=CN(CC)N=C3)=N1)C4=CC=CC=C4)[C@H]5CN(C(C=C)=O)CCC5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Guobao Zhang, et al. Pyrimidopyrroles. Patent WO2021147952A1.
molnova catalog
related products
-
BMS-986142
BMS-986142 (BMS 986142) is a potent, selective and reversible BTK inhibitor with IC50 of 0.5 nM.
-
BMS-935177
A potent and selective, orally bioavailable, reversible BTK inhibitor with IC50 of 2.8 nM.
-
Evobrutinib
A potent, highly selective BTK inhibitor for the treatment of various autoimmune disorders.Rheumatoid ArthritisPhase 2 Clinical
